{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:50:49Z","timestamp":1792086649028,"version":"4.4.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intensive Care Med"],"DOI":"10.1007\/s00134-026-08640-x","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:33:40Z","timestamp":1792085620000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Toward very early vasopressin use in septic shock: observational data accumulate but trial evidence still lacking"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3097-758X","authenticated-orcid":false,"given":"Marc","family":"Leone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1484-7539","authenticated-orcid":false,"given":"James A.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"issue":"5","key":"8640_CR1","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00134-026-08361-1","volume":"52","author":"HC Prescott","year":"2026","unstructured":"Prescott HC, Antonelli M, Alhazzani W et al (2026) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2026. Intensive Care Med 52(5):863\u2013936. https:\/\/doi.org\/10.1007\/s00134-026-08361-1","journal-title":"Intensive Care Med"},{"issue":"9","key":"8640_CR2","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/nejmoa067373","volume":"358","author":"JA Russell","year":"2008","unstructured":"Russell JA, Walley KR, Singer J et al (2008) Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358(9):877\u2013887. https:\/\/doi.org\/10.1056\/nejmoa067373","journal-title":"N Engl J Med"},{"issue":"4","key":"8640_CR3","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1097\/01.ccm.0000206466.56669.be","volume":"34","author":"M Leone","year":"2006","unstructured":"Leone M, Boyle WA (2006) Decreased vasopressin responsiveness in vasodilatory septic shock\u2013like conditions. Crit Care Med 34(4):1126\u20131130. https:\/\/doi.org\/10.1097\/01.ccm.0000206466.56669.be","journal-title":"Crit Care Med"},{"issue":"5","key":"8640_CR4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1001\/jama.2016.10485","volume":"316","author":"AC Gordon","year":"2016","unstructured":"Gordon AC, Mason AJ, Thirunavukkarasu N et al (2016) Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA 316(5):509\u2013518. https:\/\/doi.org\/10.1001\/jama.2016.10485","journal-title":"JAMA"},{"issue":"12","key":"8640_CR5","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1097\/ccm.0000000000004023","volume":"47","author":"LA Hajjar","year":"2019","unstructured":"Hajjar LA, Zambolim C, Belletti A et al (2019) Vasopressin versus norepinephrine for the management of septic shock in cancer patients: the VANCS II randomized clinical trial. Crit Care Med 47(12):1743\u20131750. https:\/\/doi.org\/10.1097\/ccm.0000000000004023","journal-title":"Crit Care Med"},{"issue":"19","key":"8640_CR6","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1001\/jama.2025.3046","volume":"333","author":"A Kalimouttou","year":"2025","unstructured":"Kalimouttou A, Kennedy JN, Feng J et al (2025) Optimal vasopressin initiation in septic shock: the OVISS reinforcement learning study. JAMA 333(19):1688\u20131698. https:\/\/doi.org\/10.1001\/jama.2025.3046","journal-title":"JAMA"},{"issue":"1","key":"8640_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-025-05401-y","volume":"29","author":"KC White","year":"2025","unstructured":"White KC, Costa-Pinto R, Blank S et al (2025) Effect of early adjunctive vasopressin initiation for septic shock patients: a target trial emulation. Crit Care 29(1):188. https:\/\/doi.org\/10.1186\/s13054-025-05401-y","journal-title":"Crit Care"},{"key":"8640_CR8","doi-asserted-by":"publisher","unstructured":"Nakashima T, Ichinomiya T, Nakajima M et al (2026) Ultra-early versus early adjunctive vasopressin initiation after norepinephrine escalation in septic shock: a target trial emulation. Intensive Care Med https:\/\/doi.org\/10.1007\/s00134-026-08575-3","DOI":"10.1007\/s00134-026-08575-3"},{"issue":"11","key":"8640_CR9","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00134-019-05801-z","volume":"45","author":"JA Russell","year":"2019","unstructured":"Russell JA (2019) Vasopressor therapy in critically ill patients with shock. Intensive Care Med 45(11):1503\u20131517. https:\/\/doi.org\/10.1007\/s00134-019-05801-z","journal-title":"Intensive Care Med"},{"issue":"3","key":"8640_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.accpm.2023.101193","volume":"42","author":"M Leone","year":"2023","unstructured":"Leone M, Einav S, Antonucci E et al (2023) Multimodal strategy to counteract vasodilation in septic shock. Anaesth Crit Care Pain Med 42(3):101193. https:\/\/doi.org\/10.1016\/j.accpm.2023.101193","journal-title":"Anaesth Crit Care Pain Med"},{"issue":"3","key":"8640_CR11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/fjc.0000000000001796","volume":"87","author":"D Dal-Secco","year":"2026","unstructured":"Dal-Secco D, Olivon VC, Celes MRN et al (2026) Vascular hyporesponsiveness in sepsis is associated with nitric oxide-dependent activation of g-protein receptor kinase. J Cardiovasc Pharmacol 87(3):183\u2013191. https:\/\/doi.org\/10.1097\/fjc.0000000000001796","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"8640_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/cc12789","volume":"17","author":"S Mehta","year":"2013","unstructured":"Mehta S, Granton J, Gordon AC et al (2013) Cardiac ischemia in patients with septic shock randomized to vasopressin or norepinephrine. Crit Care 17(3):R117. https:\/\/doi.org\/10.1186\/cc12789","journal-title":"Crit Care"},{"key":"8640_CR13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jcrc.2018.05.003","volume":"47","author":"JA Russell","year":"2018","unstructured":"Russell JA, Lee T, Singer J et al (2018) Days alive and free as an alternative to a mortality outcome in pivotal vasopressor and septic shock trials. J Crit Care 47:333\u2013337. https:\/\/doi.org\/10.1016\/j.jcrc.2018.05.003","journal-title":"J Crit Care"},{"issue":"15","key":"8640_CR14","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1001\/jama.2019.14607","volume":"322","author":"PF Laterre","year":"2019","unstructured":"Laterre PF, Berry SM, Blemings A et al (2019) Effect of selepressin vs placebo on ventilator- and vasopressor-free days in patients with septic shock. JAMA 322(15):1476\u20131485. https:\/\/doi.org\/10.1001\/jama.2019.14607","journal-title":"JAMA"},{"issue":"5","key":"8640_CR15","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1007\/s00134-026-08344-2","volume":"52","author":"M Leone","year":"2026","unstructured":"Leone M, Myatra SN, Dugar S et al (2026) Clinical criteria for the definition of refractory septic shock: a joint Delphi consensus from the Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM). Intensive Care Med 52(5):984\u20131000. https:\/\/doi.org\/10.1007\/s00134-026-08344-2","journal-title":"Intensive Care Med"}],"container-title":["Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-026-08640-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00134-026-08640-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-026-08640-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:33:42Z","timestamp":1792085622000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00134-026-08640-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":15,"alternative-id":["8640"],"URL":"https:\/\/doi.org\/10.1007\/s00134-026-08640-x","relation":{},"ISSN":["0342-4642","1432-1238"],"issn-type":[{"value":"0342-4642","type":"print"},{"value":"1432-1238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"15 October 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ML: Dr. Leone served as speaker for Viatris, AOP Pharma, and consultant for Advanz, Aguettant, Previa, Provepharm, Solventum. JAR: Dr. Russell reports patents owned by the University of British Columbia (UBC) that are related to: (1) the use of PCSK9 inhibitor(s) in sepsis, (2) the use of vasopressin in septic shock, (3) a patent owned by Ferring for use of selepressin in septic shock and (4) nucleic acid therapeutics for treatment of or pre-treatment for severe bacterial infections and complications thereof. Dr. Russell is an inventor on these patents. Dr. Russell is a shareholder in Molecular You Corp. Dr. Russell is a co-founder, officer, Director and shareholder of Resolve Nanotherapeutics. Dr. Russell was (2022 -2024) the Senior Research Advisor of the Post COVID-19 - Inter-disciplinary Clinical Care Network (PC-ICCN) of British Columbia, Canada. Dr. Russell is not consulting for any industry. Dr. Russell was the non-funded Chair of the Data and Safety Monitoring Board (DSMB) of a trial (UC CISS II) of stem cells in sepsis. Since 2021, Dr. Russell has received grants for COVID-19, for community acquired pneumonia (CAP) and for bacterial drug(s) and vaccine(s) research as follows: 6 from the Canadian Institutes of Health Research (CIHR), 3 from the St. Paul\u2019s Foundation (SPF), 4 from Government of Canada Mitacs grants, and 1 each from: The Rix Family Foundation, Canada\u2019s Immunology and Biomanufacturing Hub (CIEBH)\/CBRF, Genome British Columbia (GBC), Canadian Foundation for Innovation (CFI) and British Columbia Lung Foundation.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}